Trial Profile
A Randomized, Double-Blinded, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Effect of DAPAglifozin and Stress ( i.v. ACTH) on the Development of DKA After Insulin Withdrawal in Adolescent and Adult Subjects With T1D
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Tetracosactide (Primary)
- Indications Diabetic ketoacidosis; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Dapa-Stress
- 02 Jun 2023 Status changed from recruiting to discontinued.
- 03 Aug 2022 Planned End Date changed from 1 Jun 2022 to 1 Oct 2023.
- 03 Aug 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.